← FDA DRUG APPROVALS

FDA ANDA · ANDA062538

DOXYCYCLINE HYCLATE

Sponsor: STRIDES PHARMA INTL

APPLICATION
ANDA062538
TYPE
ANDA
ORIGINAL APPROVAL
1986-04-07
LATEST ACTION
2026-02-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DOXYCYCLINE HYCLATEPrescription
DOXYCYCLINE HYCLATE EQ 100MG BASE · TABLET · ORAL
DOXYCYCLINE HYCLATEPrescription
DOXYCYCLINE HYCLATE EQ 50MG BASE · TABLET · ORAL

Approval history

2026-02-06Labeling · Supplement 22 · standardAP
2026-02-06Labeling · Supplement 21 · standardAP
2025-03-31Labeling · Supplement 19 · standardAP
2025-03-27Labeling · Supplement 14 · standardAP
2025-03-27Labeling · Supplement 17 · standardAP
2025-03-27Labeling · Supplement 13 · standardAP
1993-03-16Manufacturing (CMC) · Supplement 9AP
1991-02-23Manufacturing (CMC) · Supplement 8AP
1989-05-08Manufacturing (CMC) · Supplement 7AP
1986-04-07OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →